CHICAGO, February 10, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune ...

Tempus AI, Inc. (NASDAQ: TEM) stock rose Monday after the company released preliminary fourth-quarter and full-year 2025 results on Sunday and announced new contracts. For 2025, the company reported ...

This is an edition of The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here. A ...

Tempus AI remains a Buy after a market-driven correction, with operational performance and partnerships strengthening the long-term thesis. TEM's organic revenue grew 28% y/y, gross margins improved ...

Tempus AI TEM is developing and deploying a suite of advanced algorithms and diagnostic software that run on its multimodal data. These algorithms span beyond oncology, including digital pathology, ...

Tempus AI (NASDAQ:TEM) shares are trading higher Monday after the company announced its subsidiary, Ambry Genetics, published a peer reviewed study in Genetics in Medicine. What To Know: Tempus ...

Tempus AI specializes in developing artificial intelligence solutions to improve patient outcomes in various healthcare fields. Ark Invest reduced the Tempus AI position in the ARK Innovation ETF.

Shares of Tempus AI climbed after federal regulators gave special clearance to the company's AI-powered cardiac imaging platform, Tempus Pixel. The stock was up 12% at $87.64 in early trading. Shares ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Chicago health system is ...

Sci-Fi Movies Ryan Gosling's space odyssey wows in final trailer for cosmic sci-fi thriller Project Hail Mary, but Rocky is the real MVP Movies Edgar Wright And More Big Names Screened Project Hail ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial-intelligence-powered programs for spotting the signs of cancer. The deal totals $81.25 million, ...